Ignite Creation Date:
2024-05-05 @ 11:55 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00171184
Status:
COMPLETED
Last Update Posted:
2017-05-18
First Post:
2005-09-12
Brief Title:
Efficacy Safety and Tolerability of Darifenacin in Patients Aged 65 Years With Overactive Bladder
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
Efficacy Safety and Tolerability of Darifenacin in Patients Aged 65 Years With Overactive Bladder
Status:
COMPLETED
Status Verified Date:
2017-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The objective of this study is to assess the efficacy safety and tolerability of 12-weeks treatment with darifenacin in patients aged Ý 65 years with OAB
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None